Background and Objectives: Breast cancer is the most common cancer in women, with approximately 80% being oestrogen receptor positive, necessitating adjuvant endocrine therapy (AET) to reduce recurrence. Treatment adherence is crucial, yet 10–50% of patients take incorrect doses or discontinue therapy, which is associated with a 20% increase in mortality. AET may also impact bone health. This study aimed to explore patients’ beliefs about endocrine treatment, investigate how perceptions of medication risk and benefit affect adherence, and assess changes in bone mineral density (BMD) during therapy. Materials and Methods: A cross-sectional mixed-method study was conducted. One hundred patients diagnosed with oestrogen receptor-positive breast cancer in 2020 were sent the Beliefs about Medicines Questionnaire–Adjuvant Endocrine Therapy (BMQ-AET) and 101 semi-structured telephone interviews were completed. Initial and most recent Dual-Energy X-ray Absorptiometry (DEXA) scans were compared to assess changes in BMD. Results: The questionnaire response rate was 55% (n = 55). Forty-nine patients returned the postal paper survey and six patients responded via QR code. One hundred and one patients participated in semi-structured telephone interviews. Of the total cohort, 91.7% were adherent to AET, while 13 patients (8.3%) were non-adherent. Non-adherent patients had significantly lower BMQ-AET Necessity scores (mean 12.08 vs. 19.22; median 12 vs. 20; p < 0.001) and higher Concerns scores (mean 17 vs. 13.46; Median 17 vs. 13; p = 0.002). The most common reasons for non-adherence were joint pain and reduced quality of life (58%), highlighting a need for additional support in managing side effects. Among the participants with suitable DEXA data, the majority (54.2%) demonstrated an increase in BMD over time. Conclusions: This study demonstrates high adherence to AET, with non-adherent patients showing lower perceived necessity and greater concern about treatment. These findings emphasise the importance of addressing patient beliefs to enhance adherence. The observed improvements in BMD suggest that proactive bone health management, alongside AET, may mitigate expected declines, challenging conventional assumptions regarding therapy-related bone loss.
Introduction Breast cancer is the most common cancer in women, with 80% being oestrogen receptor positive, requiring endocrine treatment to reduce recurrence. Treatment compliance is vital; however, 10-50% of patients take an incorrect dosage or discontinue therapy. This has shown a 20% mortality increase. Additionally, endocrine therapy has been said to negatively impact patient’s bone health. This study’s aim is to explore patient’s beliefs about endocrine treatment, how perception of medication risk and benefit affects adherence; as well as investigate the treatments effect on bone health. Methods: 100 patients diagnosed with oestrogen receptor positive breast cancer in 2020 were sent the Beliefs about Medicine Questionnaire-Adjuvant Endocrine Therapy (BMQ-AET). A further 101 semi-structured telephone interviews were conducted. Initial and recent DEXA scans were compared to assess bone density changes. Results The response rate for the questionnaire was 55%(N=55). 49 patients returned the postal paper survey, and 6 patients responded via QR code. 101 patients participated in semi-structured telephone interviews. 13 patients were non-adherent (8.3%). Non-adherent patients showed decreased BMQ-AET Necessity scores and higher scores for BMQ-AET Concerns subscales. Joint pain and poor quality of life were the most common reason for non-adherence, 58%(N=97), which confirmed the need for more help managing side effects. BMQ-AET NECESSITY SCORE N MEAN P-VALUE NON-ADHERENT 13 17.54 < 0.001 ADHERENT 143 10.86 BMQ-AET CONCERNS SCORE N MEAN P-VALUE NON-ADHERENT 13 13 0.002 ADHERENT 143 16.54 Of participants suitable for DEXA comparison, the majority (54.2%) showed an increase in bone density. Conclusion This study demonstrated good compliance to endocrine treatment. Non-adherent patients showed significantly low BMQ-AET necessity and high BMQ-AET concerns subscale scores. This highlights that patient’s non-adherent to AET have a lowered perception of necessity and greater concern regarding the medication, confirming a further need to address patient’s beliefs about endocrine treatment. DEXA comparison showed increased BMD, which challenges the previously held beliefs.